PDS Biotech VERSATILE-002 abstract accepted for ESMO 2024 presentation

PDS Biotechnology Corp

Abstract on first-line Versamune HPV + KEYTRUDA in HPV16-positive recurrent/metastatic HNSCC accepted for ESMO.
Poster number 879P; session at ESMO Congress 2024 in Barcelona, Sept 13-17.
Presenting author: Dr. Jared Weiss, Section Chief at UNC and trial PI.
Poster title includes survival data; no clinical results disclosed in this release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.